Remove Hospitals Remove RNA Remove Virus
article thumbnail

Simple test for flu could improve diagnosis and surveillance

Broad Institute

Simple test for flu could improve diagnosis and surveillance By Allessandra DiCorato June 18, 2024 Breadcrumb Home Simple test for flu could improve diagnosis and surveillance A low-cost CRISPR-based paper strip test distinguishes between influenza types and can be reprogrammed to recognize different viruses including the H5N1 bird flu virus.

Virus 144
article thumbnail

Preliminary Findings from a Phase 2a Trial of Investigational COVID-19 Therapeutic Molnupiravir

The Pharma Data

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scientists map the locations of hundreds to thousands of cell types across a mammalian brain

Broad Institute

One study was led by senior authors Evan Macosko , an institute member at the Broad and associate professor and attending psychiatrist at Massachusetts General Hospital, and Fei Chen , a core institute member at the Broad and an assistant professor in the Department of Stem Cell and Regenerative Biology at Harvard University.

DNA 140
article thumbnail

Targeted drug treatment leads tumor cells to imitate viral infection

Broad Institute

Targeted drug treatment leads tumor cells to imitate viral infection By Ari Navetta July 11, 2024 Breadcrumb Home Targeted drug treatment leads tumor cells to imitate viral infection Exploiting "viral mimicry," mIDH1 inhibitors trick tumors into thinking they are infected with a virus. paper cited Wu M, Kondo H, et al.

article thumbnail

BioCryst Provides Update on Galidesivir Program

The Pharma Data

(Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral, galidesivir, showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2, the virus that causes COVID-19. It is in advanced development for the treatment of Marburg virus disease.

article thumbnail

Neutralizing Antibody Shows Potential for Mild-to-Moderate COVID-19

The Pharma Data

30, 2020 — Viral load was decreased at day 11 for patients with mild or moderate COVID-19 who received a single intravenous infusion of virus-neutralizing monoclonal antibody versus placebo, according to a study published online Oct. percent of viral RNA at day 11. FRIDAY, Oct. 28 in the New England Journal of Medicine.

RNA 52
article thumbnail

Phase 2/3 Studies of Molnupiravir, an Investigational Oral Antiviral Therapeutic for Mild to Moderate COVID-19.

The Pharma Data

The Phase 3 portion of the global MOVe-OUT trial studying molnupiravir in non-hospitalized adult patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes is underway. About Molnupiravir.